Trial Profile

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC 022 (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

08 Dec 2020 Results reporting data on an anti-CD19/CD22 dual CAR-T therapy based on a novel manufacturing platform, in treating patients with B-cell acute lymphoblastic leukemia presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
04 Nov 2020 According to a Gracell Biotechnology media release, data from this study will be presented at the 62nd ASH Annual Meeting and Exposition in December.
04 Nov 2020 Results published in the Gracell Biotechnology Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com